MedTrace Logo

Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee

NCT00393393 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2006-10-27

No results posted yet for this study

Summary

That Hylan G-F 20 may act to protect cartilage from the expected degree of degradation over a 12 month period in subjects with moderate to marked osteoarthritis of the knee

Conditions

Interventions

DRUG

intra-articular injection of Hylan G-F 20

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • Cabrini Medical Centre

    lead OTHER

Principal Investigators

  • stephen hall, MBBS, FRACP · Cabrini Medical Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2006-01-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00393393 on ClinicalTrials.gov